Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could less dialysis be better for seniors? new study aims to find out

NCT ID NCT06141798

Disease control Sponsor: Soonchunhyang University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares starting dialysis twice a week versus the standard three times a week in elderly patients (60+) with end-stage kidney disease who still produce some urine. The goal is to see if fewer sessions reduce hospitalizations, falls, and other complications while maintaining quality of life. Over 400 participants will be followed for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hemodialysis (number of sessions per week)
What this could lead to
If successful, this could show that starting dialysis twice a week is safer and reduces hospital stays for elderly patients, potentially changing standard care.
What could go wrong
This is a pragmatic trial, but results may not apply to all patients. Twice-weekly dialysis might not control toxins well enough, and the study is limited to those with residual kidney function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 428 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥60 years * Clinical diagnosis of end stage kidney disease * Starting maintenance hemodialysis within one month * 24-hour urine output ≥ 500 ml at randomization * Sufficient understanding of the study procedures and requirements. Exclusion Criteria: * Left ventricular ejection fraction \< 40%) * Liver cirrhosis * Current treatment for an active malignancy or active infection * Onability or refusal to provide written informed consent * enrollment in another clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age problem are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure Frailty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age problem Dialysis; complications Frailty Quality of life

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hallym University Medical Center- Chuncheon

    COMPLETED

    Chuncheon, South Korea

  • Kangbuk Samsung Medical Center

    COMPLETED

    Seoul, South Korea

  • Koera University Guro Hospital

    COMPLETED

    Seoul, South Korea

  • Soonchunhyang University Hospital Bucheon

    RECRUITING

    Bucheon-si, South Korea

  • Soonchunhyang University Seoul Hospital

    ACTIVE_NOT_RECRUITING

    Seoul, 04401, South Korea

  • The Catholic University of Korea, Yeouido St. Mary's Hospital

    COMPLETED

    Seoul, South Korea

  • Yonsei University, Wonju Severance Christian Hospital

    COMPLETED

    Wŏnju, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.